Does A9509 require prior authorization?

No, A9509 does not require prior authorization (high confidence). Covered without prior authorization.

What is the Medicare reimbursement rate for A9509?

Medicare facility rate: N/A. Non-facility rate: N/A. Work RVU: 0.00.

Backwork Sign up free

`A9509`, Iodine i-123 sodium iodide, diagnostic, per millicurie

HCPCS/CPT

Prior Authorization

No Prior Auth Required

Covered without prior authorization (high confidence)

Medicare Pricing

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

Documentation Required

Parathyroid localization enhanced by dual-isotope subtraction and/or ultrasound with iPTH assay in US-guided FNA: documentation of ultrasound and iPTH aspirate results when performed to direct surgical approach.
Sentinel node procedures: documentation of preoperative lymphoscintigraphy (when performed), intraoperative lymphatic mapping technique, and definitive histopathology of sentinel node(s) (only individuals with histologically confirmed sentinel node metastases are selected for radical node dissection).

AdreView (iobenguane I-123) diagnostic standard: “The diagnosis was determined by histopathology or, when histopathology was unavailable, a composite of imaging, plasma/urine catecholamine and/or catecholamine metabolite measurements and clinical follow-up.” (implies need for histopathology or detailed composite diagnostic documentation).

For therapeutic radiopharmaceuticals (e.g., 131I-MIBG, 90Y-DOTATOC): documentation of diagnostic uptake on corresponding imaging (demonstrating sufficient uptake to deliver therapeutic dose), dosimetry data, and clinical status to justify individualized therapy; monitoring of thyroid, liver, hematologic function pre- and post-therapy as described in studies.

For tumor-induced osteomalacia (TIO): documentation of acquired hypophosphatemia with renal phosphate wasting, inappropriately low plasma calcitriol, and localization imaging such as total body MRI, octreotide (indium-111) scintigraphy or PET/CT (text: tumor localization may involve octreotide scintigraphy).

For cervical cancer SLNB candidate selection (UpToDate): documentation supporting the four widely accepted criteria: "Tumors of less than 4 cm; No suspicious lymph nodes identified during pre-operative imaging; Bilateral SLN detection; Ultra-staging (i.e., enhanced pathologic review, including additional sectioning and staining of the SLN)."

Key Coverage Criteria

ProstaScint scans medically necessary for pre-operative staging of newly diagnosed members with biopsy-proven prostate cancer that is thought to be clinically localized after standard diagnostic evaluation, but who have a moderate to high probability of occult extra-prostatic metastasis.
ProstaScint scans medically necessary for staging of post-prostatectomy members or members treated with radiation therapy in whom there is a high suspicion of undetected residual prostate cancer or cancer recurrence.
Oncoscint (satumomab pendetide) imaging medically necessary as an alternative to second-look laparotomy to detect occult colorectal carcinoma in members with suspected recurrence suggested by an elevated carcino-embryonic antigen (CEA) level, but who have no evidence of disease on conventional imaging modalities (including CT scan).
Oncoscint imaging medically necessary for detection of occult colorectal carcinoma in members about to undergo a potentially curative resection of an apparently isolated recurrence located at a single site (e.g., lung or liver) which has been identified on conventional imaging modalities (including CT scan) and for whom the detection of occult lesions elsewhere would alter the surgical management.
Oncoscint imaging medically necessary for detection of occult recurrent ovarian cancer in members with suspected recurrence suggested by rising tumor markers, when no other imaging or physical examination technique can locate the suspected disease.
CEA-Scan (Tc-99m-arcitumomab) medically necessary, for use in conjunction with computerized tomography (CT) scans, for detection of recurrent or metastatic colorectal cancer in the liver and extra-hepatic abdomen and pelvis.

1 Active Policy

AETNA-CPB-0168, Tumor Scintigraphy

Have a follow-up question?

Ask Backwork about documentation requirements, denial risks, or coverage in your state.

Ask Backwork about A9509 Sign up free

A9509, Iodine i-123 sodium iodide, diagnostic, per millicurie